Blocking IL-6 can significantly reduce tumor burden, which is associated with immune microenvironment remodeling and is characterized by cytotoxic CD8+T cell expansion and MDSCs reduction [80], as shown in Fig. 3. The gene discussed is CD8A; the disease is neoplasm.